Review Article - Neuropsychiatry (2017) Volume 0, Issue 0

Mechanisms of Deep Brain Stimulation for Epilepsy and Associated Comorbidities

Corresponding Author:
Guoming Luan, M.D., Ph.D
Beijing Key Laboratory of Epilepsy,
Department of Neurosurgery, Epilepsy Center,
Sanbo Brain Hospital, Capital Medical University, Beijing, China
Tel: 86-10-62856718
Fax: 86-10-62856902
E-mail: luangm3@163.com

Abstract

Deep brain stimulation (DBS) is an important effective treatment for pharmacoresistant epilepsy, but its mechanism is still not clear. In clinical application, the possible effects and mechanisms DBS in treatment of epilepsy are different according to different stimulation parameters. We reviewed the mechanisms of DBS in different frequencies including high frequency and low frequency in the treatment of epilepsy, covering the inhibition or excitation of synaptic, pathological neuronal and network activity, pathological rhythms or oscillation and neurotransmitter systems. As the onset and progression of seizure, it’s more frequent accompanied with cognitive and psychiatric comorbidities in patients with epilepsy. We review the possible mechanism of DBS in treating epilepsy associated comorbidities including cognitive and memory disorders. With the further development of clinical application and basic research of DBS, the processing of clinical individualized therapy of DBS in epilepsy and evaluation of effects of DBS in associated comorbidities may contribute to extend the understanding of the mechanisms of DBS for epilepsy and associated comorbidities.

Keywords

Epilepsy, Comorbidity, Deep brain stimulation, Neuromodulation

Introduction

Epilepsy is a common neurological disorder characterized by repeated spontaneous neurological or behavioral changes, often associated with cognitive impairment, psychiatric symptoms, and social function deficit. Worldwide prevalence of epilepsy is estimated by approximately 1% in the population [1-4]. In fact, more than 30 percent of patients with epilepsy are still unable to get adequate control of their seizures although with medicine therapy [5,6]. And surgical methods are only suitable for epilepsy patients with focal lesions clear, if the lesion is not clear or bilateral cerebral hemisphere involvement, as well as patients with higher risk of cognitive impairment, surgical methods can’t be conducted. Therefore, electrical stimulation is very important means to suppress seizures.

In fact, the use of brain electrical stimulation is not a new treatment method, but it has gained much attention in the recent more than 20 years [7]. One of the most commonly used method is the deep brain stimulation (DBS), namely through stimulating electrode implanted and connected with subcutaneous pulse generator to implement the electrical stimulation, and activation of specific brain areas and control the related brain network to achieve the therapeutic effect [8,9].

DBS was first used in the treatment of motor disorders, such as Parkinson’s disease (PD), tremor and dystonia. The good effect of DBS in treatment of motor system diseases leads to widely extended study of the basal ganglia circuits [10-14]. At the same time, it makes people to expand its scope to the treatment of other neurological diseases such as epilepsy and mental diseases such as depression, which makes a deeper understanding of the neurobiological mechanisms and brain networks of the nervous system diseases [15-19]. What’s more, DBS is a kind of controllable treatment, which has obvious individuation and reversibility. These features make DBS significantly superior to surgical resection. Moreover, in the past more than 20 years, DBS has been shown to be safer and with less complications and mortality.

▪ Applications of DBS for epilepsy

Early scientific evidences have shown potentially beneficial effects of DBS on epileptiform activity in cat models [20-22]. And then electrical stimulation in patients has also been examined in a number of relatively small human trials targeted in the cerebellum [23-25]. Along with the development of research about DBS, the targets of DBS are more diverse and abundant. In addition to the cerebellum, effective sites include hippocampus, subthalamus, hypothalamus, anterior thalamus; caudate, brainstem and seizure focus [26-28].

Among them, the anterior thalamic nucleus (ANT) is the most widely used stimulation targets. Because of the physiological replacing role of electrodes, ANT-DBS has better therapeutic effect than ANT damage [29-31]. ANT DBS has considerable protection effect in 1985 first reported by Cooper and Upton [32]. They reported a seizure reduction in the frequency of 4 in 6 patients. Furthermore, many clinical researches including multicenter, double-blind, randomized bilateral SANTE experiment of ANT-DBS in epilepsy also verify the effectiveness [33-35].

They reported in 110 patient’s 40.4% seizure decline in treatment group compared with 14.5% in the control group. After 2 years it is 56% median reduction in seizure frequency, and onset of 54% patients was reduced by 50%. 14 patients were seizure free for at least 6 months. Another including 191 subjects randomized multicenter double-blinded controlled trial of responsive focal cortical stimulation (RNS System) [36,37]. They reported a progressive and significant improvement with time as the median percent reduction in seizures was 44% at 1 year and 53% at 2 years. These clinical studies, most patients can tolerate DBS stimulation, and with no side effects of related exercise and low or no adverse effects neuropsychological function or mood.

▪ The mechanism of DBS for epilepsy

Although the clinical use of DBS has emerged for several decades, understanding of the mechanisms for the therapeutic action of DBS remains poorly defined. The therapeutic mechanism(s) of DBS may complicate. The authors reported it may involve inhibition or excitation of synaptic, pathological neuronal and network activity, pathological rhythms or oscillation and neurotransmitter systems [38-42].

However, the optimal “antiepileptic parameters” including frequency, duration, and mode of delivery (pulses vs continuous stimulation) of DBS for reducing the frequency of seizures are much variable among patients. Moreover, the suitable stimulation parameters in a patientspecific manner could lead to indispensable for antiepileptic effects. In fact, interpretation of laboratory and clinical data is challenging because of a lot of stimulation protocols used, as the different stimulation frequencies and target locations. The frequencies of stimulation display different strategies to intervene with epileptiform. We will review the mechanisms based on the frequencies. A wide range of stimulation frequencies have been used between 0.1 and 400 Hz. Studies have shown that high frequency stimulation (HFS; usually >70 Hz) and low frequency stimulation (LFS; usually <12 Hz) are beneficial for suppressing epileptic seizures. While intermediate frequencies (IFS, around 50 Hz) trigger epileptic afterdischarges, favor thalamic oscillations and entrain epileptic dynamics, and was actually used as damage method in the kindling model of epilepsy [43- 48], not involved in this review.

▪ Mechanism of high frequency DBS

Applied a high-frequency stimulation produces a direct and indirect influence on the cell bodies, dendrites or axons. HFS could produce a transient blockade of intrinsic voltage-gated currents in subthalamic nucleus, indicating single-spike and bursting modes of discharge for interrupting ongoing activities of STN neurons [49]. These effects closely related to the synaptic transmission, underlying HFS may induce the synaptic plasticity [50]. Moreover in rat hippocampal brain slices, depressed excitatory postsynaptic potentials by HFS maybe on account of the decreased presynaptic axon excitability at synapses between CA1 pyramidal neurons and Schaffer collaterals [51]. Synaptic depression induced by HFS may be due to neurotransmitter depletion, reported as decreasing in concentrations of excitatory amino acids such as glutamate and aspartate, while the enhancing of inhibitory synaptic transmission by HFS such as γ-aminobutyric acid releasing from afferent fibers and thereby [52,53]. Similarly, it’s been reported local HFS inhibits neurons of human subthalamic nucleus, which may inhibit intrinsic synaptically mediated responses as neuronal firing [54].

Modulation of the network is proposed based on the concept that disease treated with DBS are fundamentally disease of a specific brain network, rather than a specific neuron type, ion channel, or molecule [55]. In order to establish a framework related to network effects of DBS, measurements involved in cerebral blood flow and metabolic imaging, functional imaging, and electrophysiology (including scalp and intracranial electroencephalography and magnetoencephalography).Thalamocortical network is an important structure in epilepsy treat with DBS. In fact, HFS given to any location within the thalamocortical network is likely to affect the whole network. When adding glutamate release and glutamate-dependent activation of Ih, HFS may abolish thalamic network oscillations [56]. Further, HFS conducts the disruption of the thalamocortical network’s dysrhythmia by an initial excitatory mechanism and subsequently develops inhibitory processes depending on neurotransmitter release. Regarding this,HFS maybe neither only inhibitory nor excitatory, but rather perform the disruption of network oscillations and rhythmic activity [56-58]. In addition to neurons in the network, astrocytic activity has been effected by HFS, which implicating an important role of astroglia in this modality [59,60]. As astrocytes could be directly depolarized by HFS [61], regulate the inhibitory synapses in activitydependent modulation and have the potential to modulate distant/local neural networks through the release of adenosine and gliotransmitters including glutamate and ATP [62,63]. In the brain, adenosine is regarded as endogenous anticonvulsant and seizure terminator [64-66]. Furthermore, the upregulation of adenosine and its kinase during the astrogliosis as a crucial link between astrocyte and neuron dysfunction may provide a pivotal role in the abnormal network of neuron and glia in epilepsy [67-69]. Considering of possible action of adenosine in prediction and prevention of epileptogenesis [70], it will be an alternative target in mechanism of DBS in treatment of epilepsy.

▪ Mechanism of low frequency DBS

From 1980’s, electrical low-frequency stimulation (LFS) has been reported effectively treating kindled seizures [71]. With animal models and clinical applications, it has shown LFS could inhibit seizure activities and reduce frequency of seizures [72-75]. Although numerous researches have displayed the potential therapeutic effect of LFS on epileptic seizures, the underlying mechanisms are still unknown.

LFS induced long-lasting hyperpolarization underlies seizure reduction [76]. And it could decrease the discharges of interictal spiking [72]. LFS showed blockade of in vitro ictogenesis coincides with increased epileptiform response frequency-dependent increase latency in rodent brain slices, which may contribute to decrease epileptiform synchronization [77]. In bilateral hippocampal slice, LFS decreased 4-AP–induced epileptiform activity [76]. Some studies described LFS induces a transient synaptic depression that alters synaptic transmission [45]. Further, LFS in the GPe exerts therapeutic effect on seizures due to interference with delta rhythms [78]. LFS could modulate cortical oscillations with statedependent [79].

In hippocampal CA1 pyramidal cells of kindled rats, LFS application may have effects on spontaneous inhibitory and excitatory post-synaptic currents preventing seizure-induced raise in the occurrence of sEPSCs and seizure-induced decrease in occurrence and activity duration of sIPSCs [80]. Moreover, LFS could enhance the effectiveness of phenobarbital on GABAergic currents, implicating a positive interaction between phenobarbital and LFS through GABAA currents, which indicated a well effective combined therapy [81]. LFS either immediately or in close interval rapid kindling stimulation may inhibit the kindling-induced epileptogenesis [82]. It indicates LFS as an efficient technique can be used in closed loop seizure system to predict and prevent epileptic discharges.

Mechanism of DBS for epilepsy and associated comorbidities

Epilepsy patients common happen with other diseases, including nervous system disease, mental illness and physical diseases. The incidences of migraine, tic disorder, autism, attention-deficit/ hyperactivity disorder, depression, anxiety disorders, bipolar disorder and psychotic disorder are much higher than general population [83-89].

Seizures patients are often accompanied with cognitive disorders, particularly in learning and memory related functions, which often regarded as secondary to epilepsy or caused by epilepsy [90-94]. A small sample in patients with refractory temporal lobe epilepsy with amygdalohippocampal DBS showed improvement in emotional wellbeing [95]. Another research with nine patients with intractable epilepsy underwent by bilateral ANT- DBS suggested significant improvements in both verbal recall fluency tasks and oral information processing [30]. Application of LFS in kindling-induced seizure animal models improved cognitive impairment associated spontaneous alternation behavior in Y-maze test, concerning of the upregulation in calcineurin gene expression in the hippocampal area [96]. Further, application of LFS in kindle rats for a long-term could improve effect on spatial learning and memory, which show a dependence of the number of applied LFS [97]. In fact, dysfunction of epilepsy and cognition may even be bidirectional affected with each other, which in some extent share common pathological process following dysfunction of Papez circuit and limbic system including the hippocampus, which induced abnormal hippocampal-dependent behaviors, including spatial learning and memory [94,98-100]. Of interest, Helmstaedter and Witt highlighted the relevance limbic encephalitis to temporal lobe epilepsy with hippocampal atrophy and sclerosis as with successful immunomodulatory therapy, the seizures disappear as well as cognition and mood improving [94], which may provide a new cue to explore the mechanism and application of DBS.

Conclusion

Although there has been a lot of research on the mechanisms of DBS in treating epilepsy, it is still not clear. In fact, because the organism is a complex system, the mechanisms of DBS is complex and different. In this paper, we distinguish the mechanism of different frequencies of epilepsy, but the clinical application of highfrequency stimulation to treat epilepsy, while obviously the role of low frequency stimulation cannot be ignored. It has been reported the latest neuromodulator have been able to carry out high - low frequency conversion therapy, providing an important area of our individual treatment in clinic. We summary the mechanism of DBS for comorbidity of epilepsy, however unabundant, mainly because many diseases accompany epilepsy in the pathological process, they may be transformed into side effects during or after the treatment of DBS epilepsy,, such as depression. This suggests that we should be more delicate and careful in the design of clinical stimulus protocols, to ensure that the benefits of the stimulation process are maximized.

Acknowledgements

This work was supported by the National Natural Science Foundation of China (81671285), the Capital Health Research and Development of Special (2016-1-8012), Beijing Municipal Science & Technology Commission (Z161100000516230, Z161100002616016), National Key Research and Development Program (2016YFC0105902), Project supported by Beijing Postdoctoral Research Foundation (2016 ZZ-42).

References